[Interpretation of the third edition Bethesda system for reporting thyroid cytopathology].

Based on the changes of the classification and nomenclature in the fifth edition of the World Health Organization (WHO) classification of thyroid neoplasms, the third edition Bethesda system for reporting thyroid cytopathology (TBSRTC) was revised in June 2023. Two new chapters have been added: one addressing the clinical perspectives and imaging findings in thyroid disease and another summarizing the molecular test for thyroid cytology. A discussion of risk of malignancy (ROM) and clinical management algorithms for pediatric thyroid carcinoma have been added. The third edition provides an average ROM for each category, in addition to the expected range of cancer risk. This paper aims to interpret the main changes in the third edition TBSRTC and to provide guidelines for the clinical management of thyroid nodules.基于第5版世界卫生组织（WHO）甲状腺肿瘤分类及命名的更新，第3版甲状腺细胞病理Bethesda报告系统（TBSRTC）于2023年6月修订再版，新增了甲状腺结节临床与超声特征、甲状腺细胞分子检测两个章节、儿童甲状腺癌恶性风险（ROM）和临床处理原则等相关内容。同时更新了TBSRTC报告中每个分类的ROM范围，并在原有ROM范围基础上新增其平均值。本文就第3版TBSRTC的更新要点进行阐述，为甲状腺结节的规范化诊疗提供依据。.